Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner. Necroptosis, a type of programmed necrosis is defined as a death receptor-initiated process under caspase-compromised conditions. The process re...
Saved in:
Published in | PloS one Vol. 7; no. 7; p. e41945 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
31.07.2012
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner. Necroptosis, a type of programmed necrosis is defined as a death receptor-initiated process under caspase-compromised conditions. The process requires the kinase activity of receptor-interacting protein kinase 1 and 3 (RIPK1 and RIPK3) and mixed lineage kinase domain-like protein (MLKL), as a substrate of RIPK3. The further downstream events remain elusive. We applied known inhibitors to characterize the contributing enzymes in necroptosis and their effect on cell viability and different cellular functions were detected mainly by flow cytometry. Here we report that staurosporine, the classical inducer of intrinsic apoptotic pathway can induce necroptosis under caspase-compromised conditions in U937 cell line. This process could be hampered at least partially by the RIPK1 inhibitor necrotstin-1 and by the heat shock protein 90 kDa inhibitor geldanamycin. Moreover both the staurosporine-triggered and the classical death ligand-induced necroptotic pathway can be effectively arrested by a lysosomal enzyme inhibitor CA-074-OMe and the recently discovered MLKL inhibitor necrosulfonamide. We also confirmed that the enzymatic role of poly(ADP-ribose)polymerase (PARP) is dispensable in necroptosis but it contributes to membrane disruption in secondary necrosis. In conclusion, we identified a novel way of necroptosis induction that can facilitate our understanding of the molecular mechanisms of necroptosis. Our results shed light on alternative application of staurosporine, as a possible anticancer therapeutic agent. Furthermore, we showed that the CA-074-OMe has a target in the signaling pathway leading to necroptosis. Finally, we could differentiate necroptotic and secondary necrotic processes based on participation of PARP enzyme. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors have read the journal's policy and have the following conflicts: IP is an employee of KPS Medical Biotechnology and Healthcare Services Ltd. KPS Medical Biotechnology did not support our studies at all. KPS Medical Biotechnology provides molecular pathology services to detect predictive biomarkers in tumor samples for personalized targeted therapies. The company focuses on the diseases of the gastrointestinal tract and on lung cancer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Conceived and designed the experiments: RM PIB. Performed the experiments: ZAD GI GB. Analyzed the data: ZAD GI GB. Contributed reagents/materials/analysis tools: ZAD GI GB. Wrote the paper: ZAD PIB TK. Final approval of the version to be published: PIB ZAD TK RM IP. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0041945 |